Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Rheumatoid Arthritis: Update Bulletin [June 2016]

Product Code:
596200548
Publication Date:
April 2016
Format:
PDF
Price:
£1,140

Gain new KOL insights on the latest events happening in rheumatoid arthritis (RA) treatment landscape. Topics covered include reaction to the availability of a new biosimilar version of the anti-TNF, infliximab; Pfizer’s Xeljanz (tofacitinib) 5 mg tablets accepted for review by European Medicines Agency (EMA); as well as opinions on Can-Fite’s piclidenoson (CF 101).

Key Questions Answered in this Update Bulletin:

  • How will the launch of additional biosimilar infliximab products impact the RA market?
  • Will Xeljanz be approved in the EU? If so, will this product be welcomed by rheumatologists?
  • If launched in the EU, what hurdles might Xeljanz face?
  • How do KOLs view piclidenoson (CF 101), and how could piclidenoson be positioned in the RA treatment algorithm?



customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved